MATERIALS AND METHODS:
This is a single-center study on a series of 380 allogeneic HSCT between 2005 and 2015; of which 99 were either major (n = 74) or bidirectional (n = 25) ABO mismatched. Pre-transplant infusion of FFP, post-transplant complications and transfusion requirements were determined by retrospective review of individual medical records. Laboratory results were also reviewed for evidence of hemolysis and pure red cell aplasia (PRCA).
RESULTS:
Clinical manifestation of hemolysis attributable to ABO mismatch was present in one recipient of major ABO-incompatible peripheral blood stem cell (PBSC) with a titer of 64. Another recipient of major ABO-incompatible PBSC with a titer of 64 showed biochemical evidence of hemolysis. Both patients recovered with supportive treatment. Hemolysis did not occur in any patients with titer of 32 or less at the time of stem cell infusion. We were unable to demonstrate the influence of any variables on the incidence of PRCA.
CONCLUSION:
Our experience demonstrated that donor-type FFP is safe and effective in preventing acute hemolysis in major ABO-mismatched HSCT. We have also established the titer of 64 as the threshold that may cause hemolysis and therefore efforts should be made to reduce titer to below this level.
A llogeneic hematopoietic stem cell transplantation (HSCT) can be performed across the ABO blood group barrier, in contrast to solid organ transplantation. ABO incompatibility between donor and recipient occur in about 20-40% of patients undergoing HSCT. [1] [2] [3] Three groups of ABO mismatch can be distinguished in HSCT; minor, major, and bidirectional. Although ABO incompatibility between donor and recipient does not represent a barrier to successful HSCT, there are associated complications which are distinct from those associated with solid organ transplantation. Complications due to ABO mismatch arise from incompatibility due to antibodies and antigens present in the graft and recipient blood, as well as other cells of the donor and recipient immune system. 1 The immediate complication of major ABO-incompatible transplantation is the potential for serious and life-threatening hemolytic reaction. The risk of acute hemolytic reactions can be decreased by either reducing the red cell content of the graft or the isoagglutinin titers of the recipient. Reduction of recipient isoagglutinins can be accomplished by plasma exchange, immunoadsorption by infusion of donor-type fresh frozen plasma (FFP), or combination of both.
1-3 American
Society for Apheresis (ASFA) guidelines recommended that plasma exchange can be used as an alternative to red cell reduction in order to lower recipient anti-A and/or anti-B isoagglutinins and avoid manipulation of the hematopoietic progenitor cell product. 4 There is no consensus in the literature with respect to the most efficient strategy for isoagglutinin reduction in major ABO-mismatched HSCT, especially in the era of peripheral blood progenitor cell transplantation. Most centers use plasma exchange whereas there are only few publications on the successful use of donor-type secretor plasma for the purpose of isoagglutinin reduction before HSCT. 2, 3, 5, 6 The aim of our study is to evaluate the efficacy of donortype FFP in reducing isohemagglutinin titer and preventing hemolysis, as well as its effect on delayed red cell engraftment.
MATERIALS AND METHODS

Patients
This is a retrospective single-center study on a series of 380 allogeneic HSCT between 2005 and 2015. The decision to use bone marrow (BM), peripheral blood stem cell (PBSC), or umbilical cord blood as the source of HSC was determined by protocol eligibility or by recommendation of the transplant team. Pre-transplant infusion of FFP, posttransplant complications and transfusion requirements were determined by retrospective review of individual medical records. Laboratory results were also reviewed for evidence of hemolysis.
Laboratory testing
Samples from both donor and recipient were sent to the Hospital blood bank laboratory for ABO and RhD typing as well as red cell alloantibody screening by indirect antiglobulin test (IAT). In donor-recipient pairs with major ABO mismatch, samples from recipients were sent to the Blood Service Group at Health Science Authority for anti-A and anti-B titration at room temperature in saline and by IAT using gel cards technique. Unrelated donor blood groups were ascertained in advance with the relevant registry. Donor's and recipient's ABO and RhD typing were clearly recorded on the transplant protocol.
Measurement of serum bilirubin, lactate dehydrogenase (LDH), transaminases, haptoglobin, and hemoglobin (Hb) were performed after stem cell infusion in all patients. We defined stem cell infusion related hemolysis as an increase in LDH and unconjugated bilirubin to more than two times the upper limit of normal, suppression of haptoglobin with a decrease in Hb of greater than 1 g/dL in the absence of derangement in other liver function indices, in the days after stem cell infusion.
Pure red cell aplasia (PRCA) was defined as absent or near absent erythropoiesis with normal myeloid and megakaryopoiesis on bone marrow examination done at around Day +100. For patients without Day +100 marrow study, we inferred the presence of PRCA by a persistently low Hb with low reticulocyte count despite normal white blood count and platelet count and complete donor chimerism, after other causes of anemia were excluded.
Peritransplant strategies
Harvested BM was red cell depleted. This was not done for PBSC. Recipients with corresponding anti-A or anti-B titer of 32 or higher before admission will receive 500 mL of FFP of donor ABO type daily from day −5 to day −2 (day 0 being the day of stem cell infusion), with the objective of lowering the corresponding anti-A or anti-B to 16 or lower.
Anti-A or anti-B titer were measured on day −1. Transplant physician may choose to continue with infusion of FFP of donor ABO type for recipients with persistently elevated anti-A or anti-B titer of 32 or higher.
Statistical analysis
Fisher's exact test was used to study for any relationship between the categorical variables and development of hemolysis or PRCA.
RESULTS
A total of 99 patients received BM, PBSC, or umbilical cord blood from either major (n = 74) or bidirectional (n = 25) ABO mismatched donor, as shown in Table 1 , giving an incidence of 26% in this series of 380 patients. The most common donor-recipient pairing was B into O, accounting for 28.2% of all patients. Other common pairings include A into O and A into B, accounting for 24.2% and 17.2% of patients, respectively. None of the recipients had non-AB group antibodies. Patient characteristics and demographics are shown in Table 2 .
Isoagglutinin titers
Of the patients, 70 patients had antibody titers more than 32, including 18 patients with titers of 32, 22 patients with titers of 64, 14 patients with titers of 128, 11 patients with titers of 256, and 5 patients with titers more than 512. There were 29 patients having antibody titers of 16 or lower, as shown in Table 2 . There were 79 patients that received a median of 5 days of donor ABO type FFP (range from 2 to 8 days), according to their antibody titers based on protocol or individual physician's decision. A total of 9 patients received FFP despite having titers of 16 or lower. There were 20 patients that did not receive FFP due to low antibody titer (16 or lower). None of the patients underwent plasma exchange. A reduction in titer by a median of four fold (range from 1 to 128 fold) was achieved. Figure 1 shows the antibody titers before and after FFP.
At the time of stem cell infusion, 28 patients still had antibody titers more than the target of 16 after FFP infusion, including 21 patients with titers of 32, 4 patients with titers of 64, and 3 patients with titers of 128.
Adverse reactions to FFP
No patients develop adverse reactions associated with FFP infusion. All patients received intravenous diphenhydramine as premedication before FFP infusion according to our institutional practice. Plasma used was derived from whole blood donations.
Hemolysis
Despite immunoadsorption with donor-type FFP, 7 patients still had antibody titer more than 64 at the time of stem cell infusion, as shown in Table 3 . A total of 5 of these 7 patients have donor-recipient pairings of A+ into O+. The other 2 patients have donor-recipient pairings of AB+ into A+ and AB+ into B+, respectively. Clinical manifestation of hemolysis attributable to ABO mismatch was present in one recipient of major ABO-incompatible PBSC with a titer of 64. Another recipient of major ABO-incompatible PBSC with a titer of 64 showed biochemical evidence of hemolysis. Both patients recovered with supportive treatment. Hemolysis was however not inevitable at titer of more than 64, as the other 5 patients, including 3 patients with titers of 128 at the time of stem cell infusion did not develop hemolysis. All these 7 patients received PBSC. For the 4 patients who received BM infusion with red cell depletion, the antibody titers at the time of marrow infusion were 2, 4, 16, and 32 respectively. Hemolysis did not occur in any patients with titers of 32 or less.
Pure red cell aplasia
For the analysis of PRCA incidence, 58 patients were excluded due to bleeding complications, disease relapse, ICU admission, death, and incomplete data, which made it difficult to assess for recovery of erythropoiesis. Of the remaining 41 patients included for analysis, PRCA occurred in 3 patients. All 3 patients achieved transfusion independence by 6 months post-transplant. The conditioning regimens used in these 41 patients are Fludarabine/Cyclophosphamide/Total Body Irradiation (n = 6), Busulphan/Cyclophosphamide (n = 9), Fludarabine/Bulsulphan (n = 7), Fludarabine/Melphalan (n = 4), Cyclophosphamide/Total Body Irradiation (n = 11), Fludarabine/Total body Irradiation (n = 2), VP16/Total Body Irradiation (n = 1), and Cyclophosphamide (n = 1). No significant difference in incidence of PRCA was identifiable based on pre-or post-FFP isoagglutinin titer, isoagglutinin type (anti-A vs. Anti-B), donor type (sibling vs. unrelated), or conditioning regimen (myeloablative vs. reduced intensity/nonmyeloablative).
DISCUSSION
Although major ABO incompatibility between donor and recipient has not had a dramatic impact in HSCT, it can cause immediate and delayed immunohematological complications, which are related to isoagglutinins against ABO antigens on the donor red blood cells (RBCs). Various strategies have been adopted by many centers to prevent peritransplant complications. One strategy is to deplete RBCs from HPC products before transplantation. Another approach is to reduce the titer of incompatible recipient isoagglutinins. This can be accomplished by plasma exchange or use of donor-type FFP which depletes the isoagglutinins directly by antigen-antibody binding.
In our analysis, we did not compare FFP infusion with plasma exchange as the number of patients who underwent plasma exchange was small. There is no consensus in the literature with respect to the most efficient strategy for isoagglutinin reduction.
Our data showed that donor-type FFP is effective in the reduction of isoagglutinin titers. Hemolysis did not occur in any patients with titers of 32 or lower. With our observations and in the absence of a consensus threshold as to what defines a "high-titer" anti-A and/or anti-B isoagglutinin, the findings of this review supports our practice of setting a threshold of 16, with no intervention undertaken for titers equal to or below this threshold, and isoagglutinin depletion by donor-type FFP for titers above this value. Based on this practice, a dilution of 1:32 indicates the need for intervention, which is one dilution lower than 1:64, thus giving allowance for inaccuracy in the measurement of antibody titer.
Potential complications of plasma infusion include risk of volume overload, allergic reactions, and less commonly transfusion-related acute lung injury. We did not observe any plasma infusion-related adverse events within our cohort.
PRCA occurs in about 8-26% of patients who undergo major ABO-incompatible HSCT. 6 The probable mechanism of PRCA is the persistence of recipient-derived isoagglutinins against ABO antigens on donor RBC precursors. Stussi and colleagues 7 reported that patients with PRCA had significantly higher pre-transplantation isoagglutinin titers compared to those who did not develop PRCA. A retrospective analysis by S Damodar 3 differs from previous reports which hold that reduction of anti-donor isoagglutinin levels in the recipient seems to enhance engraftment of RBC precursors. Our cohort showed only 3 of the 41 evaluable patients develop PRCA, but did not demonstrate any correlation between pre-transplantation incompatible isoagglutinin titers with PRCA post-transplant, nor did reduction of these titers with donor-type FFP make any difference to the incidence of PRCA. We were also unable to demonstrate any influence of other variables, including isoagglutinin type, donor type, or intensity of conditioning regimen, on the incidence of PRCA. The association of these variables on risk of PRCA after HSCT is unclear in the literature, with several conflicting reports to date. [8] [9] [10] [11] [12] The benefit of donortype FFP may therefore be more for prevention of acute hemolysis rather than subsequent development of PRCA.
In conclusion, our experience demonstrated that antibody adsorption by donor-type FFP is safe and effective in preventing acute hemolysis due to major ABO-mismatched stem cell infusion. This is a simple method compared to the traditional practice of plasma exchange. We have also established the titer of 64 as the threshold that may cause hemolysis and therefore efforts should be made to reduce titers to below this level. Further improvement such as choosing plasma units from only secretor donors for infusion may reduce the number of infusions required and increase the efficacy of this practice, to ensure that isoagglutinin titers can be reduced to a safe level for all patients. 13 
